Your browser doesn't support javascript.
loading
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Kato, Ken; Shah, Manish A; Enzinger, Peter; Bennouna, Jaafar; Shen, Lin; Adenis, Antoine; Sun, Jong-Mu; Cho, Byoung Chul; Özgüroglu, Mustafa; Kojima, Takashi; Kostorov, Vladimir; Hierro, Cinta; Zhu, Ying; McLean, Lee Anne; Shah, Sukrut; Doi, Toshihiko.
Affiliation
  • Kato K; National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Shah MA; Weill Cornell Medical College, New York Presbyterian Hospital, 1305 York Avenue, Room Y1247, New York, NY 10065, USA.
  • Enzinger P; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215-5450, USA.
  • Bennouna J; University Hospital of Nantes, Digestive Oncology, 1 Place Alexis Ricordeau, Nantes, 44000, France.
  • Shen L; Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, PR China.
  • Adenis A; Institut du Cancer de Montpellier, 208 Avenue des Apothicaries, Montpellier, 34298, France.
  • Sun JM; Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Seoul, Republic of Korea.
  • Cho BC; Severance Hospital, Yonsei University Health System, 50-1 Yonsei-ro, Seoul, Republic of Korea.
  • Özgüroglu M; Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Koca Mustafa Pasa Mahallesi, Cerrahpasa Caddesi No. 53, Istanbul, 34096, Turkey.
  • Kojima T; National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
  • Kostorov V; Leningrad Regional Oncology Dispensary, Ulitsa Savushkina, 126, Saint Petersburg, 197374, Russian Federation.
  • Hierro C; Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), 119-129 Pg vall d'Hebron, Barcelona, 08035, Spain.
  • Zhu Y; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
  • McLean LA; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
  • Shah S; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
  • Doi T; National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Future Oncol ; 15(10): 1057-1066, 2019 Apr.
Article in En | MEDLINE | ID: mdl-30735435
BACKGROUND: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. AIM: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Esophageal Neoplasms / Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2019 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Esophageal Neoplasms / Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2019 Document type: Article